Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Merck
AstraZeneca
McKinsey
Harvard Business School

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,445,507

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,445,507 protect, and when does it expire?

Patent 8,445,507 protects ERLEADA and is included in one NDA.

This patent has sixty-one patent family members in seventeen countries.

Summary for Patent: 8,445,507
Title:Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Abstract: A hydantoin compound useful for the prevention or treatment of hyperproliferative diseases or disorders.
Inventor(s): Jung; Michael E. (Los Angeles, CA), Sawyers; Charles L. (New York, NY), Ouk; Samedy (Los Angeles, CA), Tran; Chris (New York, NY), Wongvipat; John (New York, NY)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:12/294,881
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,445,507
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Delivery; Dosage form;

Drugs Protected by US Patent 8,445,507

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Biotech ERLEADA apalutamide TABLET;ORAL 210951-001 Feb 14, 2018 RX Yes Yes   Start Trial   Start Trial Y Y TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,445,507

PCT Information
PCT FiledMarch 27, 2007PCT Application Number:PCT/US2007/007485
PCT Publication Date:November 08, 2007PCT Publication Number: WO2007/126765

International Family Members for US Patent 8,445,507

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007243651   Start Trial
Brazil PI0709771   Start Trial
China 101454002   Start Trial
Cyprus 1114623   Start Trial
Cyprus 1117540   Start Trial
Cyprus 1117958   Start Trial
Cyprus 1118026   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Mallinckrodt
Express Scripts
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.